What is active surveillance and when is it the right choice for cancer
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Active Surveillance in Cancer Care
Active surveillance is a carefully monitored approach where patients with certain cancers are closely watched with regular testing and imaging instead of immediately starting treatment. It's a legitimate medical strategy for specific situations—not a "wait and see" approach, but rather "watch and measure."
How Active Surveillance Works
Rather than treating cancer right away, your care team:
- Schedules regular appointments (often every 3-6 months initially)
- Performs imaging scans (CT, MRI, PET) on a set schedule
- Monitors blood tests and tumor markers
- Watches for signs that the cancer is growing or changing
- Starts treatment promptly if progression is detected
The goal is to avoid unnecessary treatment while catching any changes early enough to treat effectively.
When Active Surveillance May Be Appropriate
Active surveillance is most commonly used for:
Early-Stage Prostate Cancer
- Low-risk prostate cancer (low PSA levels, low Gleason scores, small tumors) is a classic candidate. According to NCCN Guidelines for Prostate Cancer, active surveillance can be appropriate for men with localized, low-risk disease, as many of these cancers grow very slowly or not at all.
Early-Stage Breast Cancer
- Some ductal carcinoma in situ (DCIS) may be candidates. The American Cancer Society notes that for certain low-risk DCIS cases, active surveillance is being studied as an alternative to immediate surgery.
Certain Lymphomas
- Indolent (slow-growing) lymphomas like follicular lymphoma may not require immediate treatment. The Leukemia & Lymphoma Society indicates that "watch and wait" approaches are standard for asymptomatic, early-stage indolent lymphomas.
Thyroid Cancer
- Small papillary thyroid cancers may be monitored without immediate surgery in selected cases.
Why Choose Active Surveillance?
Potential benefits:
- Avoids side effects of treatment (surgery, chemotherapy, radiation) if cancer isn't progressing
- Reduces anxiety and life disruption for slow-growing cancers
- Preserves treatment options for later if needed
- May improve quality of life in the short term
Important considerations:
- Requires commitment to regular follow-up appointments
- Requires emotional tolerance for living with a cancer diagnosis without active treatment
- Works best for cancers known to grow slowly
- Requires a trustworthy relationship with your care team
When Active Surveillance Is NOT Appropriate
Active surveillance is generally not suitable for:
- Aggressive, fast-growing cancers
- Advanced-stage disease
- Cancers with high-risk features
- Patients who cannot tolerate the psychological stress of monitoring
- Situations where treatment delays could significantly impact outcomes
Questions to Ask Your Oncologist
If active surveillance is being discussed for your situation:
- "Why is active surveillance appropriate for my specific cancer type and stage?"
- "What are the specific criteria that would trigger starting treatment?"
- "How often will I need appointments and imaging, and what will be monitored?"
- "What is the risk that my cancer will progress during surveillance, and how would we catch it?"
- "What are my alternatives, and why is active surveillance better than immediate treatment in my case?"
- "If I start active surveillance and change my mind, can I switch to treatment?"
The Bottom Line
Active surveillance is a valid, evidence-based approach for specific, carefully selected cancers—particularly slow-growing types caught at early stages. It's not about avoiding treatment indefinitely; it's about avoiding unnecessary treatment while maintaining close oversight. The NCCN Guidelines across multiple cancer types recognize active surveillance as an appropriate option when specific clinical criteria are met.
However, whether it's right for you depends entirely on your cancer type, stage, risk factors, and personal preferences. This is a decision that requires detailed discussion with your oncology team.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2
It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated
Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter